BBOT
BridgeBio Oncology Therapeutics Inc.
Biotechnology
Market Cap$185M
5Y Perf.-24.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BBOT vs BBIO
Revenue, margins, valuation, and 5-year total return — side by side.
BBIO
BridgeBio Pharma, Inc.
Biotechnology
Market Cap$13.08B
5Y Perf.+97.5%
BBOT vs BBIO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BBOT | BBIO |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $185M | $13.08B |
| Revenue (TTM) | $0.00 | $566M |
| Net Income (TTM) | $-134M | $-726M |
| Gross Margin | — | 95.1% |
| Operating Margin | — | -100.8% |
| Total Debt | $3M | $2.73B |
| Cash & Equiv. | $374M | $570M |
BBOT vs BBIO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BBOT
BBIO
| Stock | Feb 24 | May 26 | Return |
|---|---|---|---|
| BridgeBio Oncology … (BBOT) | 100 | 75.9 | -24.1% |
| BridgeBio Pharma, I… (BBIO) | 100 | 197.5 | +97.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BBOT vs BBIO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BBOT and BBIO are tied at the top with 2 categories each — the right choice depends on your priorities. BridgeBio Pharma, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
BBOT
BridgeBio Oncology Therapeutics Inc.
The Income Pick
BBOT has the current edge in this matchup, primarily because of its strength in income & stability and sleep-well-at-night.
- beta 0.96
- Lower volatility, beta 0.96, Low D/E 0.7%, current ratio 12.14x
- Beta 0.96, current ratio 12.14x
Best for: income & stability and sleep-well-at-night
BBIO
BridgeBio Pharma, Inc.
The Growth Play
BBIO is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 126.3%, EPS growth -31.6%, 3Y rev CAGR 86.3%
- 144.8% 10Y total return vs BBOT's -22.9%
- 126.3% revenue growth vs BBOT's -80.5%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BBIO | 126.3% revenue growth vs BBOT's -80.5% |
| Stability / Safety | BBOT | Beta 0.96 vs BBIO's 1.23 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | BBIO | +88.3% vs BBOT's -27.6% |
| Efficiency (ROA) | BBOT | -41.9% ROA vs BBIO's -66.2%, ROIC -96.3% vs -5.2% |
BBOT vs BBIO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
BBOT vs BBIO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBBIOLAGGINGBBOT
BBOTBridgeBio Oncology Th…
1leads
BBIOBridgeBio Pharma, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs BBOTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BBIO1/1
Valuation MetricsMultiples, price ratios, and targets
BBIO1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BBOT6/6
Total Returns1Y, 3Y, 5Y total returns with dividends
BBIO6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BBIO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
BBIO and BBOT operate at a comparable scale, with $566M and $0 in trailing revenue.
| Metric | BBOTBridgeBio Oncolog… | BBIOBridgeBio Pharma,… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $566M |
| EBITDAEarnings before interest/tax | -$166M | -$563M |
| Net IncomeAfter-tax profit | -$134M | -$726M |
| Free Cash FlowCash after capex | -$95M | -$454M |
| Gross MarginGross profit ÷ Revenue | — | +95.1% |
| Operating MarginEBIT ÷ Revenue | — | -100.8% |
| Net MarginNet income ÷ Revenue | — | -128.2% |
| FCF MarginFCF ÷ Revenue | — | -80.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +54.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -21.2% | +4.5% |
BBIO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
BBIO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | BBOTBridgeBio Oncolog… | BBIOBridgeBio Pharma,… |
|---|---|---|
| Market CapShares × price | $185M | $13.1B |
| Enterprise ValueMkt cap + debt − cash | -$186M | $15.2B |
| Trailing P/EPrice ÷ TTM EPS | -1.83x | -17.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 26.04x |
| Price / BookPrice ÷ Book value/share | 0.60x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
BBIO leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
BBOT leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), BBOT scores 4/9 vs BBIO's 2/9, reflecting mixed financial health.
| Metric | BBOTBridgeBio Oncolog… | BBIOBridgeBio Pharma,… |
|---|---|---|
| ROE (TTM)Return on equity | -65.5% | — |
| ROA (TTM)Return on assets | -41.9% | -66.2% |
| ROICReturn on invested capital | -96.3% | -5.2% |
| ROCEReturn on capital employed | -48.0% | -80.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 |
| Debt / EquityFinancial leverage | 0.01x | — |
| Net DebtTotal debt minus cash | -$371M | $2.2B |
| Cash & Equiv.Liquid assets | $374M | $570M |
| Total DebtShort + long-term debt | $3M | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | — | -10.41x |
BBOT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
BBIO leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BBIO five years ago would be worth $14,043 today (with dividends reinvested), compared to $7,713 for BBOT. Over the past 12 months, BBIO leads with a +88.3% total return vs BBOT's -27.6%. The 3-year compound annual growth rate (CAGR) favors BBIO at 70.9% vs BBOT's -8.3% — a key indicator of consistent wealth creation.
| Metric | BBOTBridgeBio Oncolog… | BBIOBridgeBio Pharma,… |
|---|---|---|
| YTD ReturnYear-to-date | -36.0% | -13.8% |
| 1-Year ReturnPast 12 months | -27.6% | +88.3% |
| 3-Year ReturnCumulative with dividends | -22.9% | +398.9% |
| 5-Year ReturnCumulative with dividends | -22.9% | +40.4% |
| 10-Year ReturnCumulative with dividends | -22.9% | +144.8% |
| CAGR (3Y)Annualised 3-year return | -8.3% | +70.9% |
BBIO leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — BBOT and BBIO each lead in 1 of 2 comparable metrics.
Risk & Volatility
BBOT is the less volatile stock with a 0.96 beta — it tends to amplify market swings less than BBIO's 1.23 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BBIO currently trades 79.4% from its 52-week high vs BBOT's 52.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BBOTBridgeBio Oncolog… | BBIOBridgeBio Pharma,… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.96x | 1.23x |
| 52-Week HighHighest price in past year | $14.87 | $84.94 |
| 52-Week LowLowest price in past year | $7.63 | $31.77 |
| % of 52W HighCurrent price vs 52-week peak | +52.9% | +79.4% |
| RSI (14)Momentum oscillator 0–100 | 41.2 | 38.7 |
| Avg Volume (50D)Average daily shares traded | 306K | 2.2M |
Evenly matched — BBOT and BBIO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates BBOT as "Buy" and BBIO as "Buy". Consensus price targets imply 175.7% upside for BBOT (target: $22) vs 49.1% for BBIO (target: $101).
| Metric | BBOTBridgeBio Oncolog… | BBIOBridgeBio Pharma,… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $21.67 | $100.58 |
| # AnalystsCovering analysts | 3 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.4% |
Insufficient data to determine a leader in this category.
Key Takeaway
BBIO leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). BBOT leads in 1 (Profitability & Efficiency). 1 tied.
Best OverallBridgeBio Pharma, Inc. (BBIO)Leads 3 of 6 categories
Loading custom metrics...
BBOT vs BBIO: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BBOT or BBIO a better buy right now?
Analysts rate BridgeBio Oncology Therapeutics Inc.
(BBOT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BBOT or BBIO?
Over the past 5 years, BridgeBio Pharma, Inc.
(BBIO) delivered a total return of +40. 4%, compared to -22. 9% for BridgeBio Oncology Therapeutics Inc. (BBOT). Over 10 years, the gap is even starker: BBIO returned +144. 8% versus BBOT's -22. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BBOT or BBIO?
By beta (market sensitivity over 5 years), BridgeBio Oncology Therapeutics Inc.
(BBOT) is the lower-risk stock at 0. 96β versus BridgeBio Pharma, Inc. 's 1. 23β — meaning BBIO is approximately 28% more volatile than BBOT relative to the S&P 500.
04Which is growing faster — BBOT or BBIO?
On earnings-per-share growth, the picture is similar: BridgeBio Pharma, Inc.
grew EPS -31. 6% year-over-year, compared to -1034. 8% for BridgeBio Oncology Therapeutics Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BBOT or BBIO?
BridgeBio Oncology Therapeutics Inc.
(BBOT) is the more profitable company, earning 0. 0% net margin versus -145. 3% for BridgeBio Pharma, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BBOT leads at 0. 0% versus -113. 3% for BBIO. At the gross margin level — before operating expenses — BBIO leads at 94. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BBOT or BBIO?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BBOT or BBIO better for a retirement portfolio?
For long-horizon retirement investors, BridgeBio Oncology Therapeutics Inc.
(BBOT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 96)). Both have compounded well over 10 years (BBOT: -22. 9%, BBIO: +144. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BBOT and BBIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BBOT is a small-cap quality compounder stock; BBIO is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.